Sandostatin Lar Depot

Give by intragluteal IM inj. Not currently receiving octreotide: initiate therapy with immediate-release octreotide SC inj for at least 2 weeks. Continue immediate-release octreotide therapy for ≥2 weeks, up to 3 or 4 weeks, after initial switch to LAR. Initially 20mg every 4 weeks for 2 months. After 2 months: if symptoms are controlled, may reduce to 10mg every 4 weeks; if symptoms are not controlled, may increase to max 30mg every 4 weeks. Dialysis or cirrhosis: initially 10mg every 4 weeks. Treat exacerbations with immediate-release octreotide SC inj at same dosage prior to switch.

Give by intragluteal IM inj. Not currently receiving octreotide: initiate therapy with immediate-release octreotide SC inj for at least 2 weeks. Switching from octreotide IR: initially 20mg every 4 weeks for 3months. After 3months, adjust as follows: GH≤2.5ng/mL, IGF-1 normal and clinical symptoms controlled: maintain dosage at 20mg every 4 weeks; GH≤1ng/mL, IGF-1 normal and clinical symptoms controlled: reduce to 10mg every 4 weeks; GH>2.5ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled: increase to 30mg every 4 weeks; may increase to max 40mg every 4 weeks. Pituitary irradiation recipients: withdraw therapy for 8 weeks once yearly to assess disease activity; resume if GH or IGF-1 levels increase or signs/symptoms recur.